बेबाक · Editorial
Capping trade margins on 137 cancer drugs is overdue; NPPA must now prove it at the counter
The NPPA's 30 per cent margin cap could cut cancer drug prices by up to 70 per cent, but it will count only if pharmacies comply and medicines stay on the shelves.
What the regulator has done
The National Pharmaceutical Pricing Authority has revised prices for 137 non-scheduled anti-cancer drugs by capping trade margins at 30 per cent. The order takes effect on November 9. The regulator expects prices to fall by up to 70 per cent, and in one reported case a drug priced at Rs 28,000 will cost Rs 4,840. This is a regulator using its powers for the people the market serves worst: families facing a diagnosis that can drain years of savings in a few months. The measure deserves support. It also deserves scrutiny, because a price order on paper does not guarantee a price at the pharmacy.
Why it matters
The scale of the problem explains the urgency. India is estimated to record around 1.56 million cancer cases and 902,000 deaths in 2025. Among selected Asian nations, that makes it the second-most affected country, behind only China. Behind these figures are households that may borrow heavily, sell assets, or abandon treatment halfway through. When a single course of medicine can cost tens of thousands of rupees, the gap between what is charged and what is affordable can become a matter of survival. A state that accepts that gap in an essential therapy fails the citizen it exists to protect.
The case on both sides
Industry and trade have a serious argument. Margins pay for cold chains, distribution to small towns, and the working capital of chemists who stock costly, slow-moving drugs. If margins are cut too sharply, some say, products may be withdrawn or quietly drop out of tier-two and tier-three markets. That concern deserves a hearing, and the regulator should watch for exactly that risk. The counter-argument is stronger. The cap is aimed at trade margins, the markup along the supply chain to the patient. Where a Rs 28,000 product can fall to Rs 4,840 once margins are capped at 30 per cent, it is hard to argue that the earlier spread reflected only the cost of logistics; much of it appears to have been borne by patients with little bargaining power.
The verdict
On balance, this is sound and overdue regulation. Rationalising trade margins targets the distribution layer, where pricing has often been least transparent, rather than imposing a single fixed price across the board. Its success, though, depends on things the order cannot settle by itself. Will chemists actually charge the revised prices? Will distributors keep stocking the drugs? Will patients know their rights? The expected 70 per cent reduction is a projection, not yet an outcome. The NPPA's credibility now rests on whether the saving reaches a district hospital in a remote tribal region as surely as a pharmacy counter in a metropolitan city.
The way forward
Four steps would turn a notification into a reform. First, the NPPA should publish a searchable list of all 137 revised prices and require pharmacies to display them. Second, it should work with state drug controllers to track stock levels and act quickly where a product disappears from shelves after November 9. Third, it should release a public compliance review within six months, covering both price adherence and availability. Fourth, state and central hospital procurement should benchmark against the new ceilings, so public money stops paying old prices. Done well, this becomes a model worth applying to other high-burden therapies.
A price that exists only in a gazette notification is not a price; it is a promise, and a cancer patient cannot wait for promises.
What this editorial rests on
Drawn from our live multi-newsroom feed — read the reporting at source.
An editorial is the considered opinion of the Aad Tak desk, argued from the sourced reporting above and written under our published persona, बेबाक. We name institutions, not parties. If we are wrong, we will say so. How we work →